Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update

Overview of attention for article published in Pediatric Nephrology, October 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

policy: 2 policy sources
twitter: 15 X users

patent: 2 patents
facebook: 3 Facebook pages

Citations

dimensions_citation: 42 Dimensions

Readers on

mendeley: 64 Mendeley

Summary Policy documents X Patents Facebook Dimensions citations

So far, Altmetric has seen 2 patents that reference this research output.

USE OF FENOLDOPAM FOR THE TREATMENT OF HEMOLYTIC UREMIC SYNDROME

Application WO-2019087049-A1

World Intellectual Property Organisation (WIPO)

USO DEL FENOLDOPAM PER IL TRATTAMENTO DELLA SINDROME EMOLITICO UREMICA

Application IT-201700123899-A1

Italy